Clinical Trial Update: [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating imaging tracers [18F]-MFBG, [123I]-MIBG, and [18F]-PE2I to differentiate Parkinson disease from multiple system atrophy, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia with Lewy Bodies
• Multiple System Atrophy
• Parkinson Disease

Drugs mentioned

• [123I]-MIBG (Iodine-123 labeled MIBG (123I-MIBG))
• [18F]-MFBG (18F-MFBG)
• [18F]-PE2I (18F-PE2I)

Snippet

Sponsor: prof. dr. Koen Van Laere | Conditions: Parkinson Disease, Dementia With Lewy Bodies | Phase 2, Phase 3 | Status: RECRUITING